Cometriq


Indications and Reactions:

Role Indications Reactions
Primary
Thyroid Cancer 46.1%
Prostate Cancer 20.8%
Renal Cancer 6.7%
Medullary Thyroid Cancer 5.6%
Brain Neoplasm Malignant 2.8%
Hepatic Cancer 2.8%
Metastasis 2.2%
Abdominal Pain Upper 1.7%
Lung Neoplasm Malignant 1.7%
Product Used For Unknown Indication 1.7%
Bone Cancer 1.1%
Metastases To Bone 1.1%
Metastases To Bone Marrow 1.1%
Pancreatic Carcinoma Metastatic 1.1%
Bladder Cancer 0.6%
Brain Neoplasm 0.6%
Breast Cancer 0.6%
Cholangiocarcinoma 0.6%
Connective Tissue Neoplasm 0.6%
Gastric Cancer 0.6%
Vomiting 14.7%
Off Label Use 12.7%
Weight Decreased 12.7%
Malignant Neoplasm Progression 9.8%
Death 6.9%
Nausea 4.9%
Platelet Count Decreased 3.9%
Pneumonia 3.9%
Rash 3.9%
Pain 2.9%
Paraesthesia 2.9%
Pyrexia 2.9%
Stomatitis 2.9%
Urinary Tract Infection 2.9%
Calcium Deficiency 2.0%
Myocardial Infarction 2.0%
Pain In Extremity 2.0%
Respiratory Failure 2.0%
Skin Ulcer 2.0%
Syncope 2.0%
Secondary
Thyroid Cancer 35.4%
Prostate Cancer 14.6%
Bone Cancer 12.5%
Abdominal Pain Upper 6.3%
Metastases To Bone 6.3%
Metastasis 6.3%
Hepatic Cancer 4.2%
Pineal Parenchymal Neoplasm Malignant 4.2%
Renal Cancer 4.2%
Hypocalcaemia 2.1%
Metastases To Bone Marrow 2.1%
Metastases To Liver 2.1%
Vomiting 24.2%
Platelet Count Decreased 15.2%
Off Label Use 12.1%
Metastases To Lung 6.1%
Supraventricular Tachycardia 6.1%
Arrhythmia 3.0%
Coma 3.0%
Pain 3.0%
Paraesthesia 3.0%
Pelvic Pain 3.0%
Pyrexia 3.0%
Sepsis 3.0%
Skin Ulcer 3.0%
Stomatitis 3.0%
Sudden Cardiac Death 3.0%
Swelling Face 3.0%
Syncope 3.0%

Drug Data